Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer

International Journal of Urology

Volumn 11, Issue 7, 2004, Pages 535-541

  Onozawa, Mizuki ^a   Kawai, Koji ^a,b   Yamamoto, Takahiro ^a   Hinotsu, Shiro ^a   Tsukamoto, Sadamu ^a   Hattori, Kazunori ^a   Miyanaga, Naoto ^a   Shimazui, Toru ^a   Akaza, Hideyuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NONE   (Japan)

Author keywords

Drug therapy; Lymph nodes; Metastasis; Pathology; Testicular neoplasms

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; TUMOR MARKER; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CELL VIABILITY; CLINICAL ARTICLE; HUMAN; HUMAN CELL; LYMPH NODE DISSECTION; MALE; METASTASIS; NECROSIS; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; SEMINOMA; TESTIS CANCER;

ADULT; AGED; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; RETROSPECTIVE STUDIES; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 4043178446     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2004.00832.x     Document Type: Article

References (24)

1. Puc H, Heelan R, Mazumdar M et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J. Clin. Oncol. 1996; 14: 454-60.
2. Mencel P, Motzer R, Mazumdar M, Vlamis V, Bajorin D, Bosl G. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J. Clin. Oncol. 1994; 12: 120-6.
3. Bosl G, Motzer R. Testicular germ-cell tumor. N. Engl. J. Med. 1997; 337: 242-53.
4. Steyerberg E, Marshall P, Keizer H, Habbema J. Resection of small, residual retroperitoneal masses after chemotherapy for nonseminomatous testicular cancer. Cancer 1999; 85: 1331-41.
5. Steyerberg E, Gerl A, Fossa S et al. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J. Clin. Oncol. 1998; 16: 269-74.
6. Herr H, Sheinfeld J, Puc H et al. Surgery for a postchemotherapy residual mass in seminoma. J. Urol. 1997; 157: 860-2.
7. de Santis M, Bokemeyer C, Becherer A et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J. Clin. Oncol. 2001; 19: 3740-4.
8. Fossa S, Kullmann G, Lien H, Stenwig A, Ous S. Chemotherapy of advanced seminoma: clinical significance of radiological findings before and after treatment. Br. J. Urol. 1989; 64: 530-4.
9. Friedman E, Garnick M, Stomper P, Mauch P, Harrington D, Richie J. Therapeutic guidelines and results in advanced seminoma. J. Clin. Oncol. 1985; 3: 1325.
10. Debono D, Heilman D, Einhorn L, Donohue J. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J. Clin. Oncol. 1997; 15: 1455-64.
11. The International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J. Clin. Oncol. 1997; 15: 594-603.
12. Einhorn L, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med. 1977; 87: 293-8.
13. Williams S, Birch R, Einhorn L, Irwin L, Greco F, Loehrer P. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med. 1987; 316: 1435-40.
14. Farhat F, Culine S, Theodore C, Bekradda M, TerrierLacombe M, Droz J. Cisplatin and ifosphamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience. Cancer 1996; 77: 1193-7.
15. Steyerberg E, Keizer H, Fossa S et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J. Clin. Oncol. 1995; 13: 1177-87.
16. Mazumdar M, Bajorin D, Bacik J, Higgins G, Motzer R, Bosl G. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J. Clin. Oncol. 2001; 19: 2534-41.
17. Almog R, Goldkrand J, Saulsbery R, Samsonoff C. Prediction of respiratory distress syndrome by a new colorimetric assay. Am. J. Obst. Gynecol. 1992; 166: 1827-32.
18. Aziz N, Buchan I, Taylor C, Kingsland C, Lewis-Hones I. The sperm deformity index: a reliable predictor of the outcome of oocyte fertilization in vitro. Fertil. Steril. 1996; 66: 1000-8.
19. Sasaki R, Habuchi T, Sato K et al. The clinical utility of measuring total PSA, PSA density, gamma-seminoprotein and gamma-seminoprotein/total PSA in prostate cancer prediction. Jpn J. Clin. Oncol. 2000; 30: 337-42.
20. Miyazaki J, Miyanaga N, Kawai K, Shimazui T, Takeshima T, Akaza H. High-dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer. Int. J. Urol. 2000; 7: 258-62.
21. Schultz S, Einhorn L, Conces D, Williams S, Loehrer P. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J. Clin. Oncol. 1989; 7: 1497-503.
22. Fossa S, Qvist H, Stenwig A, Lien H, Ous S, Giercksky K. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J. Clin. Oncol. 1992; 10: 569-73.
23. Mulders P, Oosterhof G, Boetes C, de Mulder P, Theeuwes A, Debruyne F. The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours. Br. J. Urol. 1990; 66: 425-9.
24. Matsuyama H, Yamamoto N, Sakatoku J et al. Predictive factors for the histologic nature of residual tumor mass after chemotherapy in patients with advanced testicular cancer. Urology 1994; 44: 392-8.